Bioequivalence Study of AG2202

To evaluate the bioequivalence of two formulations of AG2202T and AG2202R after a single oral dose administration in healthy Korean subjects under fasting conditions.

Inclusion criteria

• Subjects aged 19 years or older at the time of screening
• Subjects with a BMI of 18.0-30.0 kg/m2
• Subjects who do not have clinically significant congenital or chronic diseases and who do not have any pathological symptoms or findings as a result of general clinical examination
• Subjects who are deemed eligible based on the screening tests

Exclusion criteria

• Subjects who have taken drugs that induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose or who have taken drugs that may interfere with the investigational product within 10 days prior to the first dose
• Subjects who have taken the investigational drug within 6 months prior to the first dose
• Subjects who donated whole blood within 8 weeks prior to the first dose, or donated blood components within 2 weeks, or received a blood transfusion within 4 weeks prior to the first dose